281 related articles for article (PubMed ID: 28192186)
1. Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma.
Wu H; Yao S; Zhang S; Wang JR; Guo PD; Li XM; Gan WJ; Mei L; Gao TM; Li JM
J Hepatol; 2017 Jun; 66(6):1193-1204. PubMed ID: 28192186
[TBL] [Abstract][Full Text] [Related]
2. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
Duan F; Wu H; Jia D; Wu W; Ren S; Wang L; Song S; Guo X; Liu F; Ruan Y; Gu J
J Hepatol; 2018 Jun; 68(6):1191-1202. PubMed ID: 29454068
[TBL] [Abstract][Full Text] [Related]
4. G-Protein-Coupled Estrogen Receptor 1 Promotes Gender Disparities in Hepatocellular Carcinoma via Modulation of SIN1 and mTOR Complex 2 Activity.
Feng G; Cai J; Huang Y; Zhu X; Gong B; Yang Z; Yan C; Hu Z; Yang L; Wang Z
Mol Cancer Res; 2020 Dec; 18(12):1863-1875. PubMed ID: 32873626
[TBL] [Abstract][Full Text] [Related]
5. Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
Yao S; Zheng P; Wu H; Song LM; Ying XF; Xing C; Li Y; Xiao ZQ; Zhou XN; Shen T; Chen L; Liu YH; Lai MD; Mei L; Gao TM; Li JM
J Pathol; 2015 May; 236(1):65-77. PubMed ID: 25521828
[TBL] [Abstract][Full Text] [Related]
6. MOF upregulates the estrogen receptor α signaling pathway by its acetylase activity in hepatocellular carcinoma.
Wei S; Liu W; Sun N; Wu Y; Song H; Wang C; Wang S; Zou R; Lin L; Zeng K; Zhou B; Wang M; Luan R; Yang F; Zhao Y
Cancer Sci; 2021 May; 112(5):1865-1877. PubMed ID: 33544437
[TBL] [Abstract][Full Text] [Related]
7. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
8. CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.
Wang F; Zhao W; Gao Y; Zhou J; Li H; Zhang G; Guo D; Xie C; Li J; Yin Z; Zhang J
J Exp Clin Cancer Res; 2019 Jul; 38(1):286. PubMed ID: 31272499
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients.
Wang CJ; Guo DK; You TG; Shen DW; Wang C; Tang L; Wang J; Xu RH; Zhang H
Mol Med Rep; 2014 Dec; 10(6):3125-31. PubMed ID: 25270093
[TBL] [Abstract][Full Text] [Related]
10. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
11. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
13. The F domain of estrogen receptor α is involved in species-specific, tamoxifen-mediated transactivation.
Arao Y; Korach KS
J Biol Chem; 2018 Jun; 293(22):8495-8507. PubMed ID: 29632071
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
16. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
17. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
18. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
19. Increased long noncoding RNA LASP1-AS is critical for hepatocellular carcinoma tumorigenesis via upregulating LASP1.
Yin L; Chen Y; Zhou Y; Deng G; Han Y; Guo C; Li Y; Zeng S; Shen H
J Cell Physiol; 2019 Aug; 234(8):13493-13509. PubMed ID: 30677131
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A.
Xiong B; Huang J; Liu Y; Zou M; Zhao Z; Gong J; Wu X; Qiu C
Cell Oncol (Dordr); 2021 Apr; 44(2):329-343. PubMed ID: 33074477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
